Posts

Novo Nordisk Tests Lower Maintenance Doses of Oral Wegovy

on
Novo Nordisk has begun the OASIS-5 Phase 3 trial to identify whether lower maintenance doses of its oral Wegovy pill can still produce meaningful weight loss. The randomized, placebo-controlled study began enrolling on August 12 and will include about 450 adults with obesity or overweight across sites in the United States and Europe. Participants will receive two undisclosed lower doses of oral semaglutide or placebo for 60 weeks. The trial is expected to run until 2028. The current approved maintenance dose of oral Wegovy is 25 mg once daily, reached through a gradual dose-escalation schedule. Novo says a wider range of maintenance doses could provide physicians more flexibility and improve patients’ treatment experience, particularly for people who have difficulty tolerating the highest dose. Researchers will measure weight change as the primary outcome and also monitor waist circumference, metabolic measures, weight-loss milestones and side effects. The trial does not ye...

Genentech expands Oregon manufacturing while Bavarian Nordic delays Lyme vaccine trial

on

Lilly teams with Amplitude on RNA vaccines

on

Matwings Reports Four-Cycle Closed-Loop Protein AI Program

on

Akeso advances AK157D1 B7-H3 ADC into Phase I development

on

Roche plans $750 million expansion of Genentech’s Oregon manufacturing site

on

Merck–Moderna Cancer-Vaccine Trial Win Sends Stocks Higher

on

Regeneron’s Pasatru wins FDA approval for ultra-rare FOP bone-growth disorder

on

Lp(a): Why biotech is betting on the “diabolical” molecule

on

Clinical development enters the digital age

on

FDA approves Ultragenyx gene therapy for glycogen storage disease type Ia

on

Rebounding biotech funding could lift CDMO demand within a year

on

Merck–Moderna Personalized Cancer Vaccine Shows Positive Phase 3 Results

on